TWA
SLN

TCI Wealth Advisors’s Silence Therapeutics SLN Stock Holding History

TCI Wealth Advisors’s Portfolio SLN Stock Details SLN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-10
Closed – – 2491
2022
Q1 		$0 Hold
10
– – ﹤0.01% 2435
2021
Q4 		$0 Buy
+10
New +$231 ﹤0.01% 2494

Other funds holding SLN

LOAMU
Lombard Odier Asset Management (USA) New York $957M AUM 35.8% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Axa
Axa Paris, France $256M AUM 25.01% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

TCI Wealth Advisors's SLN Position: Q2 2022 in Review

TCI Wealth Advisors sold out of Silence Therapeutics (SLN) in Q2 2022, closing a stake of 10 shares.

TCI Wealth Advisors first reported a position in SLN in Q4 2021 and held it in 2 quarters. The position peaked at $0 in Q1 2022. 25 funds tracked by Wall St. Rank hold SLN as of Q2 2022.

  • TCI Wealth Advisors reported no remaining Silence Therapeutics position as of Q2 2022 after selling out during the quarter.
  • TCI Wealth Advisors sold 10 Silence Therapeutics shares in Q2 2022.
  • TCI Wealth Advisors first reported a position in Silence Therapeutics in Q4 2021 and held it in 2 quarters.
  • TCI Wealth Advisors's Silence Therapeutics position peaked at $0 in Q1 2022.
  • 25 funds tracked by Wall St. Rank held Silence Therapeutics as of Q2 2022.

Based on TCI Wealth Advisors's 13F filing for Q2 2022, filed 19 Jul 2022.